Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 11/20 | 0.61 |
| ▸ | ROCK2 | O75116 | 11/20 | 0.61 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.41 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PAK4 | O96013 | 1/20 | 0.38 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | PLK1 | P53350 | 1/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20168369 | 0.88 | ROCK2 (0.56) | ROCK1ROCK2ALDH1A1MAPTKDM4E | |
| SCHEMBL18254786 | 0.77 | ROCK2 (1.00) | ROCK1ROCK2 | |
| SCHEMBL20181388 | 0.76 | ROCK2 (0.70) | ROCK1ROCK2 | |
| SCHEMBL21376352 | 0.76 | ROCK2 (0.70) | ROCK1ROCK2 | |
| SCHEMBL20168500 | 0.76 | ALDH1A1 (0.47) | CSNK2A2CSNK2BCSNK2A1KDRALDH1A1 | |
| SCHEMBL30597783 | 0.76 | ALDH1A1 (0.47) | CSNK2A2CSNK2BCSNK2A1KDRALDH1A1 | |
| SCHEMBL20181637 | 0.75 | ROCK1 (0.69) | ROCK1ROCK2 | |
| SCHEMBL21376141 | 0.75 | ROCK1 (0.69) | ROCK1ROCK2 | |
| SCHEMBL20181641 | 0.75 | ROCK2 (0.55) | ROCK1ROCK2 | |
| SCHEMBL20181638 | 0.75 | ROCK2 (0.72) | ROCK1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10807966-B2 | Heterocyclic compounds as kinase inhibitors | TRANSLATIONAL DRUG DEVELOPMENT, LLC (US) | 2020-10-20 | — | — | US | disclosed |
| US-10807966-B2 | Heterocyclic compounds as kinase inhibitors | TRANSLATIONAL DRUG DEVELOPMENT, LLC (US) | 2020-10-20 | — | — | US | disclosed |
| EP-3541806-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | Translational Drug Development, LLC (US) | 2019-09-25 | — | — | EP | disclosed |
| US-20190284157-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | TRANSLATIONAL DRUG DEVELOPMENT, LLC | 2019-09-19 | — | — | US | disclosed |
| US-20190284157-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | TRANSLATIONAL DRUG DEVELOPMENT, LLC | 2019-09-19 | — | — | US | disclosed |
| WO-2018094362-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | TRANSLATIONAL DRUG DEVELOPMENT, LLC (US) | 2018-05-24 | — | — | WO | disclosed |
| WO-2018094362-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | TRANSLATIONAL DRUG DEVELOPMENT, LLC (US) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10807966-B2 | Heterocyclic compounds as kinase inhibitors | MAP3K1, MAP3K20, MAP3K5 | ROCK1 67/4885ROCK2 76/4885CSNK2A2 1254/4885 |
| US-20190284157-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | MAP3K1, MAP3K20, MAP3K5 | ROCK1 67/4885ROCK2 76/4885CSNK2A2 1254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.